The effect of hepatobel on fatty liver
Phase 3
- Conditions
- Patients with fatty liver.
- Registration Number
- IRCT20141027019705N2
- Lead Sponsor
- Arak University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not having known heart disease
Not having known kidney disease
Having abnormal liver parameters
Exclusion Criteria
Unwilling to continue study
Find sensitivity to hepatobel capsules
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improve liver function. Timepoint: Measurement of fatty liver enzymes in the beginning of the study (before the start of the study) and 6 weeks after the intervention. Method of measurement: Measuring liver enzymes using biochemical kits.;Normalizing Fatty Liver Indices (such as FLI and HSI Indicators). Timepoint: Measurement of fatty liver indices in the beginning of the study (before the start of the study) and 6 weeks after the intervention. Method of measurement: Measuring liver enzymes using biochemical kits.
- Secondary Outcome Measures
Name Time Method Improve blood sugar. Timepoint: Measurement of blood sugar in the beginning of the study (before the start of the study) and 6 weeks after the intervention. Method of measurement: Measuring blood sugar using biochemical kits.;Improve blood bilirubin. Timepoint: Measurement of blood bilirubin in the beginning of the study (before the start of the study) and 6 weeks after the intervention. Method of measurement: Measuring blood bilirubin using biochemical kits.